Emergence from general anesthesia can be associated with coughing, agitation, and hemodynamic disturbances. Remifentanil may attenuate these responses. METHODS: In a prospective, double-blind, randomized trial, we enrolled 60 adult patients undergoing nasal surgery using remifentanil-based anesthesia. During the emergence phase, the remifentanil group had remifentanil reduced to one tenth of the maintenance rate, whereas the control group had remifentanil discontinued. RESULTS: Times to awakening and tracheal extubation were similar between the two groups. During emergence, the remifentanil group (infusion rate 0.014 Ϯ 0.011 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) had a significantly lower incidence (40% vs 80%, P ϭ 0.002) and less severe coughing compared with the control group, as well as a lower incidence of nonpurposeful movement (3.3% vs 30%, P ϭ 0.006) and slower heart rates. CONCLUSIONS: Low-dose remifentanil during emergence did not prolong wake-up but reduced the incidence and severity of coughing from the endotracheal tube.
BACKGROUND:
Emergence from general anesthesia can be associated with coughing, agitation, and hemodynamic disturbances. Remifentanil may attenuate these responses. METHODS: In a prospective, double-blind, randomized trial, we enrolled 60 adult patients undergoing nasal surgery using remifentanil-based anesthesia. During the emergence phase, the remifentanil group had remifentanil reduced to one tenth of the maintenance rate, whereas the control group had remifentanil discontinued. RESULTS: Times to awakening and tracheal extubation were similar between the two groups. During emergence, the remifentanil group (infusion rate 0.014 Ϯ 0.011 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) had a significantly lower incidence (40% vs 80%, P ϭ 0.002) and less severe coughing compared with the control group, as well as a lower incidence of nonpurposeful movement (3.3% vs 30%, P ϭ 0.006) and slower heart rates. CONCLUSIONS: Low-dose remifentanil during emergence did not prolong wake-up but reduced the incidence and severity of coughing from the endotracheal tube. Emergencef rom general anesthesia can be associated with coughing, agitation, hypertension, and tachycardia, which may cause bleeding from the surgical site, and an increase in intracranial and intraocular pressures. 1 Most patients cough during emergence from general anesthesia in the presence of a tracheal tube. 2 A number of techniques have been used to prevent these adverse emergence phenomena, such as removing the tube while the patient is in a deep plane of anesthesia or the administration of local anesthetics or IV opioids. 3 The administration of IV opioids before emergence may be useful for preventing cough, agitation, and hemodynamic response but may cause delayed emergence and can be unpredictable. 4 Remifentanil has a short context-sensitive half-time. 5 Thus, a rapid shift from the deep levels of anesthesia required during surgery to lighter sedative levels during emergence may be more predictable with this drug.
The objective of this prospective, randomized, double-blind study was to evaluate, in patients undergoing nasal surgery using a remifentanil-based general anesthetic, the effect of maintaining a low-dose remifentanil infusion during emergence on the incidence of coughing, nonpurposeful movement, tachycardia, and hypertension.
METHODS
After obtaining approval from the institutional review board and patients' written informed consent, 61 ASA I-II adult patients, presenting for nasal surgery, were randomly allocated according to a computergenerated random table to one of two groups. Exclusion criteria included treatment with sedatives, antitussives, or angiotensin converting enzyme inhibitors, chronic cough, asthma, predicted difficult intubation and gastroesophageal reflux.
This was a third-party blinded study in which patients receiving remifentanil-isoflurane anesthesia were randomized to receive either low-dose remifentanil infusion or no infusion at the conclusion of surgery, to determine the incidence of coughing from the endotracheal tube during emergence. Patients received an IV induction with propofol 2 mg ⅐ kg Ϫ1 , lidocaine 1.5 mg ⅐ kg
Ϫ1
, remifentanil 1 g ⅐ kg Ϫ1 over 30 s, and rocuronium 0.6 mg ⅐ kg Ϫ1 to facilitate tracheal intubation. The tracheal tube cuff pressure was maintained at 30 cm H 2 O. The initial remifentanil infusion rate was 0.05 g ⅐ kg Ϫ1 ⅐ min Ϫ1 . Maintenance was with nitrous oxide in oxygen (66:33) and isoflurane adjusted to total additive minimum alveolar concentration of 1. Remifentanil was infused at the dose range of 0.05-0.50 g ⅐ kg Ϫ1 ⅐ min Ϫ1 using a syringe pump (Medfusion 3010 a Medex Health Care company, Duluth, GA) hidden behind a drape and titrated by changes of 0.05 g ⅐ kg Ϫ1 ⅐ min Ϫ1 to maintain systolic blood pressure between baseline and 20% lower. The mean remifentanil dose was calculated at the end of the surgery by dividing the total maintenance dose (without the induction dose) by the patient's weight and the duration of surgery. All patients had their nasal passages infiltrated with local anesthetic. At the end of surgery, patients assigned to the control group had the remifentanil infusion and isoflurane stopped, whereas patients assigned to the remifentanil group had isoflurane stopped with remifentanil reduced to one tenth of the mean remifentanil dose but not Ͻ0.01 g ⅐ kg Ϫ1 ⅐ min Ϫ1 . After endotracheal extubation, the remifentanil was also stopped. All patients received 1 g of paracetamol IV (Perfalgan, UPSA laboratories, Agen, France) 30 min before the end of surgery for postoperative pain, dexamethasone 8 mg, and ondansetron 4 mg for the prevention of postoperative nausea and vomiting (PONV). After discontinuation of isoflurane, all patients received neostigmine-glycopyrrolate for reversal of residual neuromuscular blockade and orogastric suctioning. Nitrous oxide was also terminated at this time. Discontinuation of isoflurane was defined as time zero. The emergence phase was defined from time zero until 5 min after tracheal extubation, during which the patient was intermittently stimulated at 1-2 min interval verbally or with gentle tactile stimulation. During the emergence phase, the following variables were recorded every 2 min: mean arterial blood pressure (MAP), heart rate (HR), end-tidal (ET) co 2 , ET isoflurane, Ramsay Sedation Scale, 6 (1 ϭ Anxious; agitated; 2 ϭ Cooperative, oriented, and tranquil; 3 ϭ Responds to commands only; 4 ϭ Brisk response to a light glabelar tap; 5 ϭ Sluggish response; 6 ϭ No response) time to response to verbal command, to spontaneous eye opening, and to tracheal extubation, the number and grade of coughing episodes (0: no cough; 1: mild; single cough; 2: moderate; more than 1: cough lasting for Ͻ5 s; 3: severe, sustained for more than 5 s), and the occurrence of nonpurposeful movement of the limbs. Tracheal extubation was performed when patients opened their eyes and responded to verbal command. During the first 24 h postoperatively (recovery phase), the severity of sore throat and pain were assessed using a Visual Analog Scale from 0 to 10, where 0 ϭ no pain and 10 ϭ the worst imaginable pain. The presence of PONV and the need for additional analgesics or antiemetics were recorded. Clinical management and the recording of the above-mentioned variables were done by an anesthesiologist who was blinded to the group to which the patient was assigned and who was unaware if the remifentanil infusion behind the drape was reduced or stopped during the emergence phase.
An incidence of 76% of coughing was previously reported after general anesthesia. 2 Based on the assumption that 50% reduction would be clinically significant, 30 patients in each group would be required (␣ ϭ 0.05 and ␤ ϭ 0.2). Data are presented as means Ϯ standard deviations, numbers and percentage or medians, and ranges. Statistical analyses were performed with Student's t-test or analysis of variance for multiple comparisons and Bonferroni for post hoc analysis, 2 test, Fisher's exact test, or Mann-Whitney U-test as appropriate. P Ͻ 0.05 was considered statistically significant.
RESULTS
Thirty patients in each group completed the study. One patient from the remifentanil group was excluded because he had uvulopalatoplasty in addition to nasal surgery. Patients' and operative characteristics were similar between the two groups ( Table 1) .
During the emergence phase, there were no significant differences between groups in sedation, ETco 2 , or ET isoflurane. There were also no differences in the times to eye opening, response to verbal command, or tracheal extubation. The mean remifentanil infusion rate in the remifentanil group was 0.014 Ϯ 0.011 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , ranging between 0.01 and 0.05 There was no difference in the incidence of smoking between the two groups ( Table 1) . Within the groups, there was no difference in the incidence of coughing between smokers and nonsmokers.
The incidence, number, and severity of cough were significantly higher in the control group compared with the remifentanil group (Table 2) . Similarly, nonpurposeful movement occurred more frequently in the control group compared with the remifentanil group ( Table 2) . Cough and nonpurposeful movement occurred mainly in the presence of the tracheal tube and were absent in all patients shortly after tracheal extubation. No episodes of oxygen desaturation were recorded.
Baseline MAP and HR values were comparable between the two groups. During the emergence phase, an increase in MAP occurred 2 min before tracheal extubation, at tracheal extubation, and 5 min after tracheal extubation, and an increase in HR occurred at tracheal extubation in both groups compared with baseline values. Between the two groups, MAP values were comparable. However, HR was significantly higher in the control group compared with the remifentanil group after administration of reversal, 2 min and 5 min after tracheal extubation (Fig.  1) . The incidence and severity of sore throat, hoarseness, pain, and PONV were comparable between the two groups. 
